Viral Kinetic Model
Viral dynamics models provide valuable insight into the life cycle of infectious agents. This in silico viral kinetic model reveals the challenges of monotherapy treatment: a monotherapy treatment must be initiated very early in viral infection and be quite potent. However, combination therapy where different steps of the SARS-CoV-2 life cycle are modestly impacted may be an alternate strategy. Numerous model structures have been proposed, but the model for extremely fast and short-duration replication (e.g., influenza) derive from Baccam 2006. The model used here is from Gonçalves 2020 and expands the infected cell population.
We performed simulations with this viral kinetic model and found that combinations of therapeutics targeting specific rate constants have greater probability of efficacy, especially in the treatment of early infection phase in COVID-19 patients. By targeting multiple points central to viral replication within infected host cells or release from those cells, we may be able to reduce both viral load and host cell infection. Access the full manuscript which is available as a preprint: Michael Dodds, Rajesh Krishna, Antonio Gonclaves, Craig Rayner. Model-Informed Drug Repurposing: Viral Kinetic Modeling to Prioritize Rational Drug Combinations for COVID-19. Authorea. June 12, 2020. DOI: 10.22541/au.159200535.51965254Hi
The in silico workbench is intended for use by researchers to assist with clinical trial design and for exploratory and educational purposes. It is NOT intended for use in the diagnosis, cure, mitigation or treatment of any disease. Data provided are not intended to suggest that any product and/or dosing regimen are safe and effective for any use and are for informational purposes only. Please see Terms and Conditions for additional information.